Updated:
Full-Life Technologies Co. Ltd.
Full-Life Technologies Co. Ltd. is a fully integrated radiotherapeutics company with operations in Belgium, Germany, and China.
Full-Life Technologies Co. Ltd.
Full-Life Technologies Co. Ltd. is a fully integrated radiotherapeutics company with operations in Belgium, Germany, and China. The firm was established to address oncology by leveraging the physical half-life of radionuclides for targeted therapy. Its global management team draws on decades of experience in radiopharmaceutical discovery, development, production, and logistics (per the firm). The company's strategy covers the full value chain: it designs targeting vectors such as peptides, small molecules, and single-domain antibodies, then attaches radionuclides for tumor delivery. Full-Life maintains a pipeline of drug candidates, including FL-031 and FL-801, which it presented at the American Association for Cancer Research meeting in April 2025. The firm operates across Europe and China, with offices in Shanghai, Gembloux (Belgium), and Heidelberg (Germany). In May 2025, Full-Life appointed Debora Barton, MD, as Chief Medical Officer. The firm has not disclosed its total professionals count, AUM, or funding rounds. Its investor relations and partnering contacts suggest engagement with external capital partners, though ownership structure remains private. No philanthropic foundation or adjacent investment vehicle is publicly listed. Full-Life distinguishes itself through a vertically integrated radiotechnology platform that covers production and logistics alongside drug development. This contrasts with many biotech firms that outsource manufacturing or distribution. The company also maintains separate regulatory and medical affairs functions for expanded access programs, indicating a structured approach to global commercialization.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
Gembloux, Belgium · Heidelberg, Germany
Principals
Debora Barton
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Full-Life Technologies?
Full-Life Technologies does not publicly disclose its investment committee or principal ownership structure. The firm's executive leadership includes a Chief Medical Officer, appointed in 2025, but no CEO or CIO is named on the website. Investment decisions are likely directed by the founding shareholders or a board not publicly identified.
How does Full-Life Technologies source proprietary deal flow?
Full-Life develops its own pipeline of radiotherapeutics using internal R&D across peptide, small molecule, and single-domain antibody platforms. The firm does not publicly report licensing or partnership deals. Its partnering inquiries contact suggests it evaluates external opportunities, but no specific collaborations are disclosed (per the firm).
Is Full-Life structured as a family office or a private biotech company?
Full-Life Technologies Co. Ltd. is a private limited company operating as a biotech firm, not a family office. It is headquartered in Shanghai with legal presence in Europe. The firm does not describe itself as an investment vehicle, and its primary activity is drug development, not capital management.
What investment stages does Full-Life Technologies typically target?
Full-Life focuses on preclinical through clinical-stage development of radiotherapeutics. Its pipeline includes candidates at research and clinical stages, such as FL-031 and FL-801 presented at AACR 2025. The firm does not publicly specify funding rounds or revenue stage.
Which sectors does Full-Life Technologies explicitly avoid?
Full-Life Technologies confines its activities to radiotherapeutics and oncology. It does not publicly state any excluded sectors beyond this focus.
Does Full-Life maintain philanthropic structures, and how are they separated?
Full-Life Technologies does not publicly disclose any philanthropic foundation or separate charitable entity. Its corporate structure appears limited to the drug development business.
How does Full-Life Technologies' radiotechnology platform differ from conventional biotech?
Full-Life integrates production and logistics of radiopharmaceuticals alongside drug development, a structure that reduces supply chain dependencies. The firm also operates expanded access and medical affairs functions for global regulatory compliance (per the firm).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: